Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.49 +0.98 (+1.43%)
Streaming Delayed Price Updated: 12:34 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones. 
Via MarketBeat
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results. 
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
From AstraZeneca
Via Business Wire
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now
A small amount of money can go a long way when it's invested in industry leaders with well-defined catalysts. 
Via The Motley Fool
Topics Economy Government Stocks
Exposures COVID-19 Economy Interest Rates
Why the quality investor may take a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN).
A fundamental analysis of (NASDAQ:AZN): Why Quality Investors Should Delve into ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) for Investment Opportunities. 
Via Chartmill
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Might the tariff risk for pharmaceutical stocks be less than you think? 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
3 No-Brainer Growth Stocks to Buy for Less Than $100
Via The Motley Fool
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits. 
Via Benzinga
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Political Tariff
Peering Into AstraZeneca's Recent Short Interest
Via Benzinga
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma. 
Via Benzinga
Exposures Product Safety
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it. 
Via Benzinga
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib. 
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
From AstraZeneca
Via Business Wire
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
Via The Motley Fool
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Two Sectors Just Tried And Failed - And That’s Great For Us
Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat. 
Via Talk Markets
Topics Stocks / Equities
A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug?
AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.